Back to News
Market Impact: 0.35
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
Source: zacks.com
M&A & RestructuringHealthcare & BiotechProduct LaunchesTechnology & Innovation
Novo Nordisk's latest deal with Hengrui adds a phase I-ready, once-weekly oral GLP-1/GIP candidate to its obesity and diabetes pipeline. The transaction builds on Novo's prior investments in oral drug-delivery technology and small-molecule approaches, strengthening its effort to develop more convenient alternatives to injectable incretin therapies.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- South Korea’s exports hit record high on AI boom
- US judge approves settlement allowing Paramount to acquire Warner Bros
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- Paramount Skydance prices $42 billion debt for Warner Bros deal
- Asia stocks rise on chipmaker gains, soft U.S. inflation; Nikkei outperforms